Market research
ORMP Oramed Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 167M
- P/E ratio
- 0.99
- Analyst target
- 7
- Dividend yield
- 0.0%
- Beta
- 1.28
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 167M
- P/E ratio
- 0.99
- Analyst target
- 7
- Dividend yield
- 0.0%
- Beta
- 1.28
About
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Research context
Oramed Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ORMP discussion.
5 years, 6 months ago
Oramed Pharmaceuticals Inc is currently in a long term uptrend where the price is trading 57.9% above its 200 day moving average.
From a valuation standpoint, the stock is 93.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 85.6.
Oramed Pharmaceuticals Inc's total revenue sank by 0.0% to $674K since the same quarter in the previous year.
Its net income has dropped by 119.0% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 115.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Oramed Pharmaceuticals Inc gets an overall score of 2/5.